Hypoxia-inducible factor

Source: Wikipedia, the free encyclopedia.
(Redirected from
Hypoxia-inducible factor-1
)
Chr. 14 q21-q24
Search for
StructuresSwiss-model
DomainsInterPro
Chr. 1 q21
Search for
StructuresSwiss-model
DomainsInterPro
Chr. 2 p21-p16
Search for
StructuresSwiss-model
DomainsInterPro
Chr. 1 q24
Search for
StructuresSwiss-model
DomainsInterPro
Chr. 19 q13
Search for
StructuresSwiss-model
DomainsInterPro

Hypoxia-inducible factors (HIFs) are

hypoxia.[1][2] They also respond to instances of pseudohypoxia, such as thiamine deficiency.[3][4] Both hypoxia and pseudohypoxia leads to impairment of adenosine triphosphate
(ATP) production by the mitochondria.

Discovery

The HIF transcriptional complex was discovered in 1995 by Gregg L. Semenza and postdoctoral fellow Guang Wang.[5][6][7] In 2016, William Kaelin Jr., Peter J. Ratcliffe and Gregg L. Semenza were presented the Lasker Award for their work in elucidating the role of HIF-1 in oxygen sensing and its role in surviving low oxygen conditions.[8] In 2019, the same three individuals were jointly awarded the Nobel Prize in Physiology or Medicine for their work in elucidating how HIF senses and adapts cellular response to oxygen availability.[9]

Structure

Oxygen-breathing species express the

basic helix-loop-helix (bHLH) family of transcription factors. The alpha and beta subunit are similar in structure and both contain the following domains:[11][12][13]
Hypoxia-inducible factor-1
Structure of a HIF-1a-pVHL-ElonginB-ElonginC Complex.[14]
Identifiers
SymbolHIF-1
PfamPF11413
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
HIF-1 alpha C terminal transactivation domain
SCOP2
1l3e / SCOPe / SUPFAM
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
PDB1h2k​, 1h2l​, 1l3e​, 1l8c​

Members

The following are members of the human HIF family:

Member Gene Protein
HIF-1α HIF1A hypoxia-inducible factor 1, alpha subunit
HIF-1β ARNT aryl hydrocarbon receptor nuclear translocator
HIF-2α EPAS1 endothelial PAS domain protein 1
HIF-2β ARNT2 aryl-hydrocarbon receptor nuclear translocator 2
HIF-3α HIF3A hypoxia inducible factor 3, alpha subunit
HIF-3β
 ARNT3 aryl-hydrocarbon receptor nuclear translocator 3

Function

HIF1α expression in

haematopoietic stem cells explains the quiescence nature of stem cells[16]
for being metabolically maintaining at a low rate so as to preserve the potency of stem cells for long periods in a life cycle of an organism.

The HIF signaling cascade mediates the effects of hypoxia, the state of low oxygen concentration, on the cell. Hypoxia often keeps cells from

vascular system in embryos and tumors. The hypoxia in wounds also promotes the migration of keratinocytes and the restoration of the epithelium.[17] It is therefore not surprising that HIF-1 modulation was identified as a promising treatment paradigm in wound healing.[18]

In general, HIFs are vital to development. In mammals, deletion of the HIF-1 genes results in perinatal death.[19] HIF-1 has been shown to be vital to chondrocyte survival, allowing the cells to adapt to low-oxygen conditions within the growth plates of bones. HIF plays a central role in the regulation of human metabolism.[20]

Mechanism

Nobel Prize in Physiology or Medicine 2019: How Cells Sense and Adapt to Oxygen Availability. Under normoxic conditions, Hif-1 alpha is hydroxylated at two proline residues. It then associates with VHL and is tagged with ubiquitin resulting in proteasomal degradation. Under hypoxic conditions, Hif-1 alpha translocates to the cell nucleus and associates with Hif-1 beta. This complex then binds to the HRE region of the DNA resulting in the transcription of genes that are involved in a multitude of processes including erythropoesis, glycolysis, and angiogenesis.

The alpha subunits of HIF are

E3 ubiquitin ligase, which labels them for rapid degradation by the proteasome.[21][22] This occurs only in normoxic conditions. In hypoxic conditions, HIF prolyl-hydroxylase is inhibited, since it utilizes oxygen as a cosubstrate.[23][24]

Inhibition of electron transfer in the succinate dehydrogenase complex due to mutations in the SDHB or SDHD genes can cause a build-up of succinate that inhibits HIF prolyl-hydroxylase, stabilizing HIF-1α. This is termed pseudohypoxia.

HIF-1, when stabilized by hypoxic conditions, upregulates several genes to promote survival in low-oxygen conditions. These include

promoters that contain the sequence 5'-RCGTG-3' (where R is a purine, either A or G). Studies demonstrate that hypoxia modulates histone methylation and reprograms chromatin.[25] This paper was published back-to-back with that of 2019 Nobel Prize in Physiology or Medicine winner for Medicine William Kaelin Jr.[26] This work was highlighted in an independent editorial.[27]

It has been shown that muscle

A kinase–anchoring protein (mAKAP) organized E3 ubiquitin ligases, affecting stability and positioning of HIF-1 inside its action site in the nucleus. Depletion of mAKAP or disruption of its targeting to the perinuclear (in cardiomyocytes) region altered the stability of HIF-1 and transcriptional activation of genes associated with hypoxia. Thus, "compartmentalization" of oxygen-sensitive signaling components may influence the hypoxic response.[28]

The advanced knowledge of the molecular regulatory mechanisms of HIF1 activity under hypoxic conditions contrast sharply with the paucity of information on the mechanistic and functional aspects governing

TNFα (tumour necrosis factor α) treatment, HIF-1α levels also change in an NF-κB-dependent manner.[29] HIF-1 and HIF-2 have different physiological roles. HIF-2 regulates erythropoietin production in adult life.[30]

Repair, regeneration and rejuvenation

In normal circumstances after injury HIF-1a is degraded by

prolyl hydroxylases (PHDs). In June 2015, scientists found that the continued up-regulation of HIF-1a via PHD inhibitors regenerates lost or damaged tissue in mammals that have a repair response; and the continued down-regulation of Hif-1a results in healing with a scarring response in mammals with a previous regenerative response to the loss of tissue. The act of regulating HIF-1a can either turn off, or turn on the key process of mammalian regeneration.[31][32] One such regenerative process in which HIF1A is involved is skin healing.[33] Researchers at the Stanford University School of Medicine demonstrated that HIF1A activation was able to prevent and treat chronic wounds in diabetic and aged mice. Not only did the wounds in the mice heal more quickly, but the quality of the new skin was even better than the original.[34][35][36] Additionally the regenerative effect of HIF-1A modulation on aged skin cells was described[37][38] and a rejuvenating effect on aged facial skin was demonstrated in patients.[39] HIF modulation has also been linked to a beneficial effect on hair loss.[40] The biotech company Tomorrowlabs GmbH, founded in Vienna in 2016 by the physician Dominik Duscher and pharmacologist Dominik Thor, makes use of this mechanism.[41] Based on the patent-pending HSF ("HIF strengthening factor") active ingredient, products have been developed that are supposed to promote skin and hair regeneration.[42][43][44][45]

As a therapeutic target

Anemia

Several drugs that act as selective HIF prolyl-hydroxylase inhibitors have been developed.[46][47] The most notable compounds are: Roxadustat (FG-4592);[48] Vadadustat (AKB-6548),[49] Daprodustat (GSK1278863),[50] Desidustat (ZYAN-1),[51] and Molidustat (Bay 85-3934),[52] all of which are intended as orally acting drugs for the treatment of anemia.[53] Other significant compounds from this family, which are used in research but have not been developed for medical use in humans, include MK-8617,[54] YC-1,[55] IOX-2,[56] 2-methoxyestradiol,[57] GN-44028,[58] AKB-4924,[59] Bay 87-2243,[60] FG-2216[61] and FG-4497.[62] By inhibiting prolyl-hydroxylase enzyme, the stability of HIF-2α in the kidney is increased, which results in an increase in endogenous production of erythropoietin.[63] Both FibroGen compounds made it through to Phase II clinical trials, but these were suspended temporarily in May 2007 following the death of a trial participant taking FG-2216 from fulminant hepatitis (liver failure), however it is unclear whether this death was actually caused by FG-2216. The hold on further testing of FG-4592 was lifted in early 2008, after the FDA reviewed and approved a thorough response from FibroGen.[64] Roxadustat, vadadustat, daprodustat and molidustat have now all progressed through to Phase III clinical trials for treatment of renal anemia.[48][49][50]

Inflammation and cancer

In other scenarios and in contrast to the therapy outlined above, research suggests that HIF induction in normoxia is likely to have serious consequences in disease settings with a chronic inflammatory component.[65][66][67] It has also been shown that chronic inflammation is self-perpetuating and that it distorts the microenvironment as a result of aberrantly active transcription factors. As a consequence, alterations in growth factor, chemokine, cytokine, and ROS balance occur within the cellular milieu that in turn provide the axis of growth and survival needed for de novo development of cancer and metastasis. These results have numerous implications for a number of pathologies where NF-κB and HIF-1 are deregulated, including rheumatoid arthritis and cancer.[68][69][70][71][72][73] Therefore, it is thought that understanding the cross-talk between these two key transcription factors, NF-κB and HIF, will greatly enhance the process of drug development.[29][74]

HIF activity is involved in angiogenesis required for cancer tumor growth, so HIF inhibitors such as phenethyl isothiocyanate and Acriflavine[75] are (since 2006) under investigation for anti-cancer effects.[76][77][78]

Neurology

Research conducted on mice suggests that stabilizing HIF using an HIF prolyl-hydroxylase inhibitor enhances hippocampal memory, likely by increasing erythropoietin expression.[79] HIF pathway activators such as ML-228 may have neuroprotective effects and are of interest as potential treatments for stroke and spinal cord injury.[80][81]

von Hippel–Lindau disease-associated renal cell carcinoma

Belzutifan is an hypoxia-inducible factor-2α inhibitor[82] under investigation for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma.[83][84][85][86]

References

  1. PMID 18410568
    .
  2. PMID 26997519
    .
  3. PMID 24846908
    .
  4. PMID 34685573
    .
  5. S2CID 41659164
    .
  6. ^
    PMID 7539918
    .
  7. PMID 15015563
    .
  8. ^ "Oxygen sensing – an essential process for survival". Albert Lasker Basic Medical Research Award. Albert And Mary Lasker Foundation. 2016.
  9. ^ "How cells sense and adapt to oxygen availability". The Nobel Prize in Physiology or Medicine 2019. NobelPrize.org. Nobel Media AB. 7 October 2019.
  10. S2CID 33729273
    .
  11. PMID 9301332
    .
  12. S2CID 14105830
    .
  13. S2CID 46626545
    .
  14. S2CID 19641938
    .
  15. PMID 11959990
    .
  16. PMID 27125138
    .
  17. S2CID 44049779
    .
  18. PMID 28234841
    .
  19. PMID 26505703
    .
  20. PMID 20616028
    .
  21. S2CID 4427694
    .
  22. ^ Perkel J (May 2001). "Seeking a Cellular Oxygen Sensor". The Scientist. Retrieved 7 October 2019.
  23. S2CID 2434206
    .
  24. ^ Russo E (April 2003). "Discovering HIF Regulation". The Scientist. Retrieved 7 October 2019.
  25. S2CID 78093369
    .
  26. PMID 30872525
    .
  27. S2CID 78091150
    .
  28. PMID 19109240
    .
  29. ^
    PMID 18393939
    .
  30. PMID 20444740
    .
  31. ^ eurekalert.org staff (3 June 2015). "Scientist at LIMR leads study demonstrating drug-induced tissue regeneration". eurekalert.org. Lankenau Institute for Medical Research (LIMR). Retrieved 3 July 2015.
  32. PMID 26041709
    .
  33. PMID 24804159
    .
  34. PMID 25535360
    .
  35. S2CID 196350143
    .
  36. PMID 30152571
    .
  37. ^ "duscher hif - Search Results - PubMed". PubMed. Retrieved 2020-12-04.
  38. PMID 32479616
    .
  39. S2CID 216031505
    .
  40. S2CID 212693280
    .
  41. ^ Tomorrowlabs. "Tomorrowlabs". Tomorrowlabs. Retrieved 2020-12-04.
  42. ^ "Kosmetikbranche: Wie das Beauty-Start-up Tomorrowlabs den Markt erobert". www.handelsblatt.com (in German). Retrieved 2020-12-04.
  43. ^ "Das neue Beauty-Investment von Michael Pieper - HZ". Handelszeitung (in German). Retrieved 2020-12-04.
  44. ^ andrea.hodoschek (2020-08-03). "Milliardenmarkt Anti-Aging: Start-up aus Österreich mischt mit". kurier.at (in German). Retrieved 2020-12-04.
  45. ^ "Ein Protein gegen das Altern und für das Geldverdienen". nachrichten.at (in German). Retrieved 2020-12-04.
  46. PMID 17627521
    .
  47. S2CID 179020
    .
  48. ^
    S2CID 9818825
    .
  49. ^
    PMID 27650732
    .
  50. ^
    S2CID 25100284
    .
  51. PMID 28508936
    .
  52. PMID 25392999
    .
  53. PMID 18301799
    .
  54. PMID 28002958
    .
  55. PMID 12671019
    .
  56. S2CID 16938364
    .
  57. PMID 21671859
    .
  58. PMID 24900662
    .
  59. PMID 22371073
    .
  60. PMID 27610652
    .
  61. PMID 22362605
    .
  62. S2CID 5817105
    .
  63. PMID 17557894
    .
  64. ^ "The FDA Accepts the Complete Response for Clinical Holds of FG-2216/FG-4592 for the Treatment of Anemia" (PDF). Archived from the original (PDF) on 2015-09-23. Retrieved 2008-10-28.
  65. PMID 25359381
    .
  66. S2CID 4386269
    .
  67. PMID 27454299
    .
  68. PMID 26768963
    .
  69. PMID 27445820
    .
  70. S2CID 85532042
    .
  71. PMID 29158891
    .
  72. PMID 29039125
    .
  73. S2CID 232300877
    .
  74. PMID 26513405
    .
  75. PMID 19805192
    .
  76. PMID 20546646
    .
  77. PMID 17933687
    .
  78. S2CID 21525087
    .
  79. S2CID 20395457
    .
  80. S2CID 30553076
    .
  81. PMID 28450910
    .
  82. S2CID 233371559
    .
  83. ^ "Belzutifan". SPS - Specialist Pharmacy Service. 18 March 2021. Archived from the original on 26 April 2021. Retrieved 25 April 2021.
  84. ^ "MHRA awards first 'innovation passport' under new pathway". RAPS (Press release). Retrieved 25 April 2021.
  85. ^ "Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)" (Press release). Merck. 16 March 2016. Retrieved 25 April 2021 – via Business Wire.
  86. ^ "FDA Grants Priority Review to Belzutifan for von Hippel-Lindau Disease–Associated RCC". Cancer Network. 16 March 2021. Retrieved 2021-04-26.

External links

  • Hypoxia-Inducible+Factor+1 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
  • PDBe-KB provides an overview of all the structure information available in the PDB for Human Hypoxia-inducible factor 1-alpha
  • PDBe-KB provides an overview of all the structure information available in the PDB for Human Aryl hydrocarbon receptor nuclear translocator
  • PDBe-KB provides an overview of all the structure information available in the PDB for Human Endothelial PAS domain-containing protein 1
  • PDBe-KB provides an overview of all the structure information available in the PDB for Human Hypoxia-inducible factor 3-alpha
  • short scientific animation visualises the crystal structure of the Heterodimeric HIF-1a:ARNT Complex with HRE DNA
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hypoxia-inducible_factor&oldid=1217578231"